Chemical Stability of Bortezomib Solutions in Original Manufacturer Vial at Room Temperature and in Syringe at 4c

Bortezomib is a drug used in the treatment of myeloma multiple. The experiments carried out demonstrate that bortezomib is cytotoxic for different types of neoplastic cells and reduces the tumor-like growth “in vivo” in many preclinical models of tumor, including myeloma multiple. In a recent study, was evaluated the effectiveness and security of the subcutaneous administration of bortezomib as opposed to the conventional intravenous administration. It is necessary to emphasize that the concentration of the solution used for subcutaneous administration is 2.5 mg mL-1, unlike the dissolution for intravenous injection is prepared to 1 mg mL-1. The objective of this work is to evaluate the stability of the bortezomib dissolution reconstituted with NaCl 0.9 % at 2.5 mg mL-1 concentration in original manufacturer vial at room temperature and in syringe at 40C.